Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference

Rhea-AI Summary

Seer (Nasdaq: SEER), a company focused on proteomic insights, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference in Boston. The company's management will engage in a fireside chat on August 13th at 9:00 a.m. ET.

Investors can access the presentation through a live webcast on the Investor section of Seer's website at investor.seer.bio, with an archived replay available after the event.

News Market Reaction – SEER

+0.47%

1 alert

+0.47% Session move

$124.75M Market Cap

0.8x Rel. Volume

In the trading session that priced this news, SEER gained 0.47%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 45^th Annual Growth Conference in Boston, MA.

Seer’s management is scheduled to participate in a fireside chat on Wednesday, August 13^th at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.

About Seer
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others cannot. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.

Media Contact:
Consort Partners
pr@seer.bio

Investor Inquiries:
Carrie Mendivil
investor@seer.bio

FAQ

When is Seer (SEER) presenting at the Canaccord Genuity Growth Conference?

Seer will present at a fireside chat on Wednesday, August 13th at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time.

How can investors watch Seer's presentation at the Canaccord conference?

Investors can watch the presentation via live webcast on Seer's investor relations website at investor.seer.bio. An archived replay will be available after the conference.

What is the location of the Canaccord Genuity Conference where Seer is presenting?

The Canaccord Genuity 45th Annual Growth Conference is being held in Boston, MA.

What type of company is Seer (SEER)?

Seer is a pioneer and trusted partner for deep, unbiased proteomic insights.